Edwards Lifesciences Surges 8% On Hiked Guidance, Quarterly Beat

Edwards Lifesciences (EW) stock surged over 6% after the company raised its 2025 sales and earnings outlook, capitalizing on rival Boston Scientific's withdrawal of its TAVR business from Europe. Edwards now projects 9-10% total sales growth and 6-7% TAVR sales growth, with adjusted earnings at the high end of its $2.40-$2.50 guidance. This revised outlook follows a strong June quarter where the company reported 11.9% sales growth and an 8.9% increase in TAVR sales, reinforcing its market leadership.

Analysis

Edwards Lifesciences (EW) has strengthened its market position following a significant competitive development, prompting an upward revision of its 2025 financial outlook. The company is directly benefiting from the withdrawal of a rival Boston Scientific (BSX) TAVR device from the European market, which Edwards noted resulted in a 'rebalancing of market share.' Consequently, EW raised its full-year sales growth guidance to a 9-10% range and expects adjusted earnings per share to reach the high end of its $2.40-$2.50 outlook, positioning it favorably against the analyst consensus of $2.47. This guidance is supported by a strong June quarter performance, where total sales grew 11.9% to $1.53 billion, despite a 4% year-over-year decline in adjusted earnings. The core TAVR segment sales increased 8.9% to $1.1 billion, while the smaller transcatheter mitral and tricuspid therapies division demonstrated exceptional growth, with sales surging 61.9% to $134.5 million, indicating successful portfolio diversification. The market reacted positively, with the stock jumping over 6% in after-hours trading, reversing a prior drop below its 50-day moving average.

Key Decisions for Investors

• Given the improved 2025 guidance and a clearer path to TAVR market share gains due to a competitor's setback, investors should re-evaluate Edwards' long-term growth prospects and leadership position.
• Pay close attention to the rapidly expanding transcatheter mitral and tricuspid therapies division, as its 61.9% growth rate suggests it is becoming a critical future growth driver beyond the core TAVR business.
• While the outlook is strong, investors should remain mindful of the recent 4% YoY decline in adjusted quarterly earnings and assess whether the positive news is fully reflected in the stock's valuation following its significant after-hours surge.